News | October 21, 2024
Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
